Abstract
Objective To discover pharmacotherapy prescription patterns and their statistical associations with outcomes through a clinical pathway inference framework applied on real-world data.
Materials and Methods We apply machine learning steps in our framework using a 2006 to 2020 cohort of veterans with major depressive disorder (MDD). Outpatient antidepressant pharmacy and emergency department visits, self-harm, and all-cause mortality data were extracted from the Department of Veterans Affairs Corporate Data Warehouse.
Results Our MDD cohort consisted of 252,179 individuals. During the study period there were 98,417 cases of emergency department visits, 1,016 cases of self-harm, and 1,507 deaths from all causes. The top ten prescription patterns accounted for 69.3% of the data for individuals starting antidepressants at the fluoxetine equivalent of 20-39mg. Additionally, we found associations between outcomes and dosage change.
Discussion For 252,179 Veterans who served in Iraq and Afghanistan with subsequent MDD noted in their electronic medical record, we documented and described the major pharmacotherapy prescription patterns implemented by VHA providers. Ten patterns accounted for almost 70% of the data. Associations between antidepressant usage and outcomes in observational data may be confounded. The low numbers of adverse events especially associated with all-cause mortality make our calculations imprecise. Furthermore, our outcomes are also the indications for both disease and treatment. Despite these limitations, we demonstrate the usefulness of our framework in providing operational insight into clinical practice, and our results underscore the need for increased monitoring during critical points of treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Veterans Affairs.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Oak Ridge Sitewide Institutional Review Board (IRB#: IRB00000547) determines a work using the data applied in this study to be EXEMPT based on the applicable federal regulations, including DOE O443.1C and has been approved. Approval date is 4/11/2022 and expiration date is 4/10/2023.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors